Scribe Therapeutics annual ebitda
2024
2025
Scribe Therapeutics EBITDA Growth & History (SCTX)
Scribe Therapeutics's calculated EBITDA was −$18.1M for fiscal 2025.
View full Scribe Therapeutics company overviewScribe Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$18.1M | $14.2M | — |
| 2024 | 2024-12-31 | −$32.3M | — | — |
Scribe Therapeutics quarterly ebitda
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$8.8M | $2.1M | — |
| Q1 2026 | 2026-03-31 | −$15.7M | −$13.5M | — |
| Q2 2025 | 2025-06-30 | −$10.9M | — | — |
| Q1 2025 | 2025-03-31 | −$2.3M | — | — |
Scribe Therapeutics ebitda trends
Between the periods ended 2024-12-31 and 2025-12-31, Scribe Therapeutics's ebitda increased from −$32.3M to −$18.1M, a change of $14.2M. The latest reported quarter, Q2 2026, shows −$8.8M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Scribe Therapeutics source filings ↗